BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, Fargion S. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2010;138:905-912. [PMID: 19931264 DOI: 10.1053/j.gastro.2009.11.013] [Cited by in Crossref: 182] [Cited by in F6Publishing: 170] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Ahmed U, Latham PS, Oates PS. Interactions between hepatic iron and lipid metabolism with possible relevance to steatohepatitis. World J Gastroenterol 2012; 18(34): 4651-4658 [PMID: 23002334 DOI: 10.3748/wjg.v18.i34.4651] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
2 Cauchy F, Belghiti J. A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:19-27. [PMID: 27508191 DOI: 10.2147/JHC.S44521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Takaki A, Yamamoto K. Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? World J Hepatol 2015; 7(7): 968-979 [PMID: 25954479 DOI: 10.4254/wjh.v7.i7.968] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
4 Wang C, Gong J, Wu H. Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease. Biomed Rep 2017;7:95-104. [PMID: 28804621 DOI: 10.3892/br.2017.926] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
5 Pădureanu V, Dop D, Drăgoescu AN, Pădureanu R, Mușetescu AE, Nedelcu L. Non-alcoholic fatty liver disease and hematologic manifestations (Review). Exp Ther Med 2021;22:1355. [PMID: 34659501 DOI: 10.3892/etm.2021.10790] [Reference Citation Analysis]
6 Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018; 24(30): 3361-3373 [PMID: 30122876 DOI: 10.3748/wjg.v24.i30.3361] [Cited by in CrossRef: 159] [Cited by in F6Publishing: 131] [Article Influence: 39.8] [Reference Citation Analysis]
7 Lefkowitch JH. Advances in hepatobiliary pathology: update for 2010. Clin Liver Dis 2010;14:747-62. [PMID: 21055694 DOI: 10.1016/j.cld.2010.07.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Di Rosa M, Malaguarnera L. Genetic variants in candidate genes influencing NAFLD progression. J Mol Med (Berl). 2012;90:105-118. [PMID: 21894552 DOI: 10.1007/s00109-011-0803-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
9 Zimmer V, Lammert F. Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases. Best Pract Res Clin Gastroenterol. 2011;25:269-280. [PMID: 21497744 DOI: 10.1016/j.bpg.2011.02.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
10 Mehta KJ, Farnaud SJ, Sharp PA. Iron and liver fibrosis: Mechanistic and clinical aspects. World J Gastroenterol 2019; 25(5): 521-538 [PMID: 30774269 DOI: 10.3748/wjg.v25.i5.521] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 52] [Article Influence: 19.3] [Reference Citation Analysis]
11 Caligiuri A, Gentilini A, Marra F. Molecular Pathogenesis of NASH. Int J Mol Sci. 2016;17. [PMID: 27657051 DOI: 10.3390/ijms17091575] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 13.2] [Reference Citation Analysis]
12 Seyedian SS, Hajiani E, Hashemi SJ, Masjedizadeh A, Shayesteh AA, Alavinejad P, Hormati A, Javaherforoushzadeh A, Khabazkhoob M. Relationship between serum ferritin level and transient elastography findings among patients with nonalcoholic fatty liver disease. J Family Med Prim Care 2017;6:750-4. [PMID: 29564257 DOI: 10.4103/jfmpc.jfmpc_158_17] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Choi JS, Koh IU, Lee HJ, Kim WH, Song J. Effects of excess dietary iron and fat on glucose and lipid metabolism. J Nutr Biochem. 2013;24:1634-1644. [PMID: 23643521 DOI: 10.1016/j.jnutbio.2013.02.004] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
14 Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World J Gastroenterol 2014; 20(36): 12945-12955 [PMID: 25278690 DOI: 10.3748/wjg.v20.i36.12945] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 69] [Article Influence: 10.4] [Reference Citation Analysis]
15 Aigner E, Weiss G, Datz C. Dysregulation of iron and copper homeostasis in nonalcoholic fatty liver. World J Hepatol 2015; 7(2): 177-188 [PMID: 25729473 DOI: 10.4254/wjh.v7.i2.177] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 7.4] [Reference Citation Analysis]
16 Lohöfer FK, Kaissis GA, Müller-Leisse C, Franz D, Katemann C, Hock A, Peeters JM, Rummeny EJ, Karampinos D, Braren RF. Acceleration of chemical shift encoding-based water fat MRI for liver proton density fat fraction and T2* mapping using compressed sensing. PLoS One 2019;14:e0224988. [PMID: 31730658 DOI: 10.1371/journal.pone.0224988] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
17 Nelson JE, Brunt EM, Kowdley KV. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Hepatology. 2012;56:1730-1740. [PMID: 22611049 DOI: 10.1002/hep.25856] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
18 Tran A, Gual P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin Res Hepatol Gastroenterol. 2013;37:17-29. [PMID: 23347840 DOI: 10.1016/j.clinre.2012.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
19 Lückhoff HK, Kruger FC, Kotze MJ. Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol 2015; 7(9): 1192-1208 [PMID: 26019735 DOI: 10.4254/wjh.v7.i9.1192] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ong SY, Nicoll AJ, Delatycki MB. How should hyperferritinaemia be investigated and managed? European Journal of Internal Medicine 2016;33:21-7. [DOI: 10.1016/j.ejim.2016.05.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
21 Spahis S, Delvin E, Borys JM, Levy E. Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. Antioxid Redox Signal. 2017;26:519-541. [PMID: 27452109 DOI: 10.1089/ars.2016.6776] [Cited by in Crossref: 173] [Cited by in F6Publishing: 163] [Article Influence: 28.8] [Reference Citation Analysis]
22 Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE; NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:77-85. [PMID: 21953442 DOI: 10.1002/hep.24706] [Cited by in Crossref: 260] [Cited by in F6Publishing: 242] [Article Influence: 23.6] [Reference Citation Analysis]
23 Buzzetti E, Petta S, Manuguerra R, Luong TV, Cabibi D, Corradini E, Craxì A, Pinzani M, Tsochatzis E, Pietrangelo A. Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. Liver Int 2019;39:1325-34. [PMID: 30851216 DOI: 10.1111/liv.14096] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
24 Czaja AJ. Review article: iron disturbances in chronic liver diseases other than haemochromatosis - pathogenic, prognostic, and therapeutic implications. Aliment Pharmacol Ther 2019;49:681-701. [DOI: 10.1111/apt.15173] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
25 Kim TH, Jeong CW, Jun HY, Kim YR, Kim JY, Lee YH, Yoon KH. Noninvasive Differential Diagnosis of Liver Iron Contents in Nonalcoholic Steatohepatitis and Simple Steatosis Using Multiecho Dixon Magnetic Resonance Imaging. Acad Radiol. 2018;. [PMID: 30143402 DOI: 10.1016/j.acra.2018.06.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Mangano K, Fagone P, Di Mauro M, Ascione E, Maiello V, Milicic T, Jotic A, Lalic NM, Saksida T, Stojanovic I, Selmi C, Farina C, Stosic-Grujicic S, Meroni P, Nicoletti F. The immunobiology of apotransferrin in type 1 diabetes. Clin Exp Immunol 2012;169:244-52. [PMID: 22861364 DOI: 10.1111/j.1365-2249.2012.04619.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
27 Kinner S, Reeder SB, Yokoo T. Quantitative Imaging Biomarkers of NAFLD. Dig Dis Sci. 2016;61:1337-1347. [PMID: 26848588 DOI: 10.1007/s10620-016-4037-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
28 Rostoker G, Vaziri ND. Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution. Hemodial Int 2017;21 Suppl 1:S68-77. [PMID: 28332306 DOI: 10.1111/hdi.12557] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
29 Paisant A, Boulic A, Bardou-Jacquet E, Bannier E, d'Assignies G, Lainé F, Turlin B, Gandon Y. Assessment of liver iron overload by 3 T MRI. Abdom Radiol (NY) 2017;42:1713-20. [PMID: 28224171 DOI: 10.1007/s00261-017-1077-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
30 Lu S, Mott JL, Harrison-Findik DD. Saturated fatty acids induce post-transcriptional regulation of HAMP mRNA via AU-rich element-binding protein, human antigen R (HuR). J Biol Chem 2015;290:24178-89. [PMID: 26304124 DOI: 10.1074/jbc.M115.648212] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
31 Landemaine A, Hamdi-Roze H, Cunat S, Loustaud-Ratti V, Causse X, Si Ahmed SN, Drenou B, Bureau C, Pelletier G, De Kerguenec C, Ganne-Carrie N, Durupt S, Laine F, Loréal O, Ropert M, Detivaud L, Morcet J, Aguilar-Martinez P, Deugnier YM, Bardou-Jacquet E. A simple clinical score to promote and enhance ferroportin disease screening. J Hepatol 2021:S0168-8278(21)02163-2. [PMID: 34748893 DOI: 10.1016/j.jhep.2021.10.022] [Reference Citation Analysis]
32 Heritage M, Jaskowski L, Bridle K, Campbell C, Briskey D, Britton L, Fletcher L, Vitetta L, Subramaniam VN, Crawford D. Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in Hfe-/- mice. World J Gastrointest Pathophysiol 2017; 8(2): 67-76 [PMID: 28573069 DOI: 10.4291/wjgp.v8.i2.67] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Shu XB, Zhang L, Huang J, Ji G. Relationship between iron overload and nonalcoholic fatty liver disease: An update. Shijie Huaren Xiaohua Zazhi 2016; 24(22): 3398-3403 [DOI: 10.11569/wcjd.v24.i22.3398] [Reference Citation Analysis]
34 Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC, Liaquat H, Mezzabotta L, Lee E, Bugianesi E. Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:1163-1169.e1. [PMID: 24342745 DOI: 10.1016/j.cgh.2013.11.035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
35 Dallio M, Romeo M, Gravina AG, Masarone M, Larussa T, Abenavoli L, Persico M, Loguercio C, Federico A. Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives. Nutrients 2021;13:1679. [PMID: 34063372 DOI: 10.3390/nu13051679] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Dongiovanni P, Romeo S, Valenti L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int 2015;2015:460190. [PMID: 26273621 DOI: 10.1155/2015/460190] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 11.1] [Reference Citation Analysis]
37 Bertol FS, Araujo B, Jorge BB, Rinaldi N, De Carli LA, Tovo CV. Role of micronutrients in staging of nonalcoholic fatty liver disease: A retrospective cross-sectional study. World J Gastrointest Surg 2020; 12(6): 269-276 [PMID: 32774765 DOI: 10.4240/wjgs.v12.i6.269] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
39 Valenti L, Nobili V, Al-Serri A, Rametta R, Leathart JB, Zappa MA, Dongiovanni P, Fracanzani AL, Alterio A, Roviaro G. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol. 2011;55:1409-1414. [PMID: 21777557 DOI: 10.1016/j.jhep.2011.03.035] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
40 Stickel F, Hampe J. Dissecting the evolutionary genetics of iron overload in non-alcoholic fatty liver disease. J Hepatol 2010;53:793-4. [PMID: 20739088 DOI: 10.1016/j.jhep.2010.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A, Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 2011;53:448-457. [PMID: 21274866 DOI: 10.1002/hep.24038] [Cited by in Crossref: 171] [Cited by in F6Publishing: 159] [Article Influence: 14.3] [Reference Citation Analysis]
42 Afsari A, Lee E, Shokrani B, Boortalary T, Sherif ZA, Nouraie M, Laiyemo AO, Alkhalloufi K, Brim H, Ashktorab H. Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C. Dig Dis Sci 2017;62:2159-65. [PMID: 28612194 DOI: 10.1007/s10620-017-4626-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
43 Kowdley KV. The role of iron in nonalcoholic fatty liver disease: the story continues. Gastroenterology. 2010;138:817-819. [PMID: 20116466 DOI: 10.1053/j.gastro.2010.01.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
44 Mann JP, Raponi M, Nobili V. Clinical implications of understanding the association between oxidative stress and pediatric NAFLD. Expert Rev Gastroenterol Hepatol. 2017;11:371-382. [PMID: 28162008 DOI: 10.1080/17474124.2017.1291340] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 4.6] [Reference Citation Analysis]
45 Lefere S, Tacke F. Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. JHEP Rep. 2019;1:30-43. [PMID: 32149275 DOI: 10.1016/j.jhepr.2019.02.004] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 22.7] [Reference Citation Analysis]
46 Valenti L, Dongiovanni P, Fargion S. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18(29): 3782-3786 [PMID: 22876027 DOI: 10.3748/wjg.v18.i29.3782] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
47 Jung DH, Lee YJ, Park B. Longitudinal Effect of Hemoglobin Concentration With Incident Ischemic Heart Disease According to Hepatic Steatosis Status Among Koreans. Front Cardiovasc Med 2021;8:677040. [PMID: 34124205 DOI: 10.3389/fcvm.2021.677040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Shpyleva S, Pogribna M, Cozart C, Bryant MS, Muskhelishvili L, Tryndyak VP, Ross SA, Beland FA, Pogribny IP. Interstrain differences in the progression of nonalcoholic steatohepatitis to fibrosis in mice are associated with altered hepatic iron metabolism. J Nutr Biochem. 2014;25:1235-1242. [PMID: 25256357 DOI: 10.1016/j.jnutbio.2014.06.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
49 Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res 2011;52:593-617. [PMID: 21245030 DOI: 10.1194/jlr.R008896] [Cited by in Crossref: 83] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
50 Anstee QM, Seth D, Day CP. Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1728-1744.e7. [PMID: 26873399 DOI: 10.1053/j.gastro.2016.01.037] [Cited by in Crossref: 121] [Cited by in F6Publishing: 116] [Article Influence: 20.2] [Reference Citation Analysis]
51 Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism 2016;65:1026-37. [DOI: 10.1016/j.metabol.2015.08.018] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 9.7] [Reference Citation Analysis]
52 Jézéquel C, Lainé F, Laviolle B, Kiani A, Bardou-Jacquet E, Deugnier Y. Both hepatic and body iron stores are increased in dysmetabolic iron overload syndrome. A case-control study. PLoS One 2015;10:e0128530. [PMID: 26030828 DOI: 10.1371/journal.pone.0128530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
53 Corradini E, Buzzetti E, Dongiovanni P, Scarlini S, Caleffi A, Pelusi S, Bernardis I, Ventura P, Rametta R, Tenedini E, Tagliafico E, Fracanzani AL, Fargion S, Pietrangelo A, Valenti LV. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. Journal of Hepatology 2021;75:506-13. [DOI: 10.1016/j.jhep.2021.03.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Calderaro J, Zafrani ES. [Non-alcoholic fatty liver disease]. Ann Pathol 2010;30:413-20. [PMID: 21167426 DOI: 10.1016/j.annpat.2010.10.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Yeh MM, Brunt EM. Pathological Features of Fatty Liver Disease. Gastroenterology 2014;147:754-64. [DOI: 10.1053/j.gastro.2014.07.056] [Cited by in Crossref: 184] [Cited by in F6Publishing: 162] [Article Influence: 23.0] [Reference Citation Analysis]
56 Pietrangelo A. Iron and the liver. Liver Int. 2016;36 Suppl 1:116-123. [PMID: 26725908 DOI: 10.1111/liv.13020] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
57 Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, Burdick L, Frugoni C, Fracanzani AL, Fargion S. Serum Hepcidin and Macrophage Iron Correlate With MCP-1 Release and Vascular Damage in Patients With Metabolic Syndrome Alterations. ATVB 2011;31:683-90. [DOI: 10.1161/atvbaha.110.214858] [Cited by in Crossref: 59] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
58 Fujita N, Takei Y. Iron overload in nonalcoholic steatohepatitis. Adv Clin Chem. 2011;55:105-132. [PMID: 22126026 DOI: 10.1016/b978-0-12-387042-1.00006-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
59 Wilman HR, Parisinos CA, Atabaki-Pasdar N, Kelly M, Thomas EL, Neubauer S, Mahajan A, Hingorani AD, Patel RS, Hemingway H, Franks PW, Bell JD, Banerjee R, Yaghootkar H; IMI DIRECT Consortium. Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration. J Hepatol 2019;71:594-602. [PMID: 31226389 DOI: 10.1016/j.jhep.2019.05.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
60 Noor MT, Tiwari M, Kumar R. Non-HFE iron overload as a surrogate marker of disease severity in patients of liver cirrhosis. Indian J Gastroenterol 2016;35:33-9. [PMID: 26873085 DOI: 10.1007/s12664-016-0623-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Hernaez R, Yeung E, Clark JM, Kowdley KV, Brancati FL, Kao WH. Hemochromatosis gene and nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2011;55:1079-1085. [PMID: 21354231 DOI: 10.1016/j.jhep.2011.02.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
62 Daly AK, Ballestri S, Carulli L, Loria P, Day CP. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2011;5:253-263. [PMID: 21476920 DOI: 10.1586/egh.11.18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
63 Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;37:720-729. [PMID: 23441892 DOI: 10.1111/apt.12255] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
64 Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16(42): 5286-5296 [PMID: 21072891 DOI: 10.3748/wjg.v16.i42.5286] [Cited by in CrossRef: 230] [Cited by in F6Publishing: 210] [Article Influence: 19.2] [Reference Citation Analysis]
65 Muto Y, Moroishi T, Ichihara K, Nishiyama M, Shimizu H, Eguchi H, Moriya K, Koike K, Mimori K, Mori M, Katayama Y, Nakayama KI. Disruption of FBXL5-mediated cellular iron homeostasis promotes liver carcinogenesis. J Exp Med 2019;216:950-65. [PMID: 30877170 DOI: 10.1084/jem.20180900] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
66 Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J 2017;135:277-95. [DOI: 10.1590/1516-3180.2016.0306311216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
67 Kim CW, Chang Y, Sung E, Shin H, Ryu S. Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism. 2012;61:1182-1188. [PMID: 22386931 DOI: 10.1016/j.metabol.2012.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
68 Altamura S, Müdder K, Schlotterer A, Fleming T, Heidenreich E, Qiu R, Hammes HP, Nawroth P, Muckenthaler MU. Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload. Mol Metab 2021;51:101235. [PMID: 33872860 DOI: 10.1016/j.molmet.2021.101235] [Reference Citation Analysis]
69 Wood KL, Miller MH, Dillon JF. Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease. BMJ Open Gastroenterol 2015;2:e000019. [PMID: 26462272 DOI: 10.1136/bmjgast-2014-000019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
70 Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. Journal of Hepatology 2011;55:920-32. [DOI: 10.1016/j.jhep.2011.05.008] [Cited by in Crossref: 183] [Cited by in F6Publishing: 172] [Article Influence: 16.6] [Reference Citation Analysis]
71 Dekkers IA, Lamb HJ. Clinical application and technical considerations of T1 & T2(*) mapping in cardiac, liver, and renal imaging. Br J Radiol 2018;91:20170825. [PMID: 29975154 DOI: 10.1259/bjr.20170825] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
72 Liu R, Wu K, Li Y, Sun R, Li X. Human antigen R: A potential therapeutic target for liver diseases. Pharmacol Res 2020;155:104684. [PMID: 32045667 DOI: 10.1016/j.phrs.2020.104684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
73 Rametta R, Meroni M, Dongiovanni P. From Environment to Genome and Back: A Lesson from HFE Mutations. Int J Mol Sci 2020;21:E3505. [PMID: 32429125 DOI: 10.3390/ijms21103505] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
74 Dawson AJ, Sathyapalan T, Smithson JA, Vince RV, Coady AM, Ajjan R, Kilpatrick ES, Atkin SL. A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2014;80:843-849. [PMID: 23746214 DOI: 10.1111/cen.12258] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
75 Manne V, Handa P, Kowdley KV. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clin Liver Dis 2018;22:23-37. [PMID: 29128059 DOI: 10.1016/j.cld.2017.08.007] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 16.2] [Reference Citation Analysis]
76 Ye Q, Qian BX, Yin WL, Wang FM, Han T. Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls. PLoS One 2016;11:e0163423. [PMID: 27657935 DOI: 10.1371/journal.pone.0163423] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
77 Sikorska K, Bernat A, Wroblewska A. Molecular pathogenesis and clinical consequences of iron overload in liver cirrhosis. Hepatobiliary Pancreat Dis Int 2016;15:461-79. [PMID: 27733315 DOI: 10.1016/s1499-3872(16)60135-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
78 Rametta R, Dongiovanni P, Pelusi S, Francione P, Iuculano F, Borroni V, Fatta E, Castagna A, Girelli D, Fargion S, Valenti L. Hepcidin resistance in dysmetabolic iron overload. Liver Int 2016;36:1540-8. [PMID: 26998752 DOI: 10.1111/liv.13124] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
79 Cauchy F, Fuks D, Zarzavadjian Le Bian A, Belghiti J, Costi R. Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol 2014; 6(5): 306-314 [PMID: 24868324 DOI: 10.4254/wjh.v6.i5.306] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
80 Reiniers MJ, van Golen RF, van Gulik TM, Heger M. Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver. Antioxid Redox Signal. 2014;21:1119-1142. [PMID: 24294945 DOI: 10.1089/ars.2013.5486] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 7.4] [Reference Citation Analysis]
81 Valenti L, Rametta R, Dongiovanni P, Motta BM, Canavesi E, Pelusi S, Pulixi EA, Fracanzani AL, Fargion S. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS One 2012;7:e48804. [PMID: 23144979 DOI: 10.1371/journal.pone.0048804] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
82 Agrawal S, Duseja AK. Non-alcoholic Fatty Liver Disease: East Versus West. J Clin Exp Hepatol 2012;2:122-34. [PMID: 25755421 DOI: 10.1016/S0973-6883(12)60101-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
83 Paganoni R, Lechel A, Vujic Spasic M. Iron at the Interface of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:4097. [PMID: 33921027 DOI: 10.3390/ijms22084097] [Reference Citation Analysis]
84 Fan J, Kim S, Wong VW. New trends on obesity and NAFLD in Asia. Journal of Hepatology 2017;67:862-73. [DOI: 10.1016/j.jhep.2017.06.003] [Cited by in Crossref: 348] [Cited by in F6Publishing: 342] [Article Influence: 69.6] [Reference Citation Analysis]
85 Ackerman Z, Pappo O, Link G, Glazer M, Grozovski M. Liver toxicity of thioacetamide is increased by hepatocellular iron overload. Biol Trace Elem Res 2015;163:169-76. [PMID: 25161090 DOI: 10.1007/s12011-014-0110-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
86 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
87 Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48:97-113. [PMID: 21875310 DOI: 10.3109/10408363.2011.596521] [Cited by in Crossref: 183] [Cited by in F6Publishing: 171] [Article Influence: 16.6] [Reference Citation Analysis]
88 Juzėnas S, Kupčinskas J, Valantienė I, Šumskienė J, Petrenkienė V, Kondrackienė J, Kučinskas L, Kiudelis G, Skiecevičienė J, Kupčinskas L. Association of HFE gene C282Y and H63D mutations with liver cirrhosis in the Lithuanian population. Medicina (Kaunas) 2016;52:269-75. [PMID: 27816425 DOI: 10.1016/j.medici.2016.09.004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
89 Corradini E, Pietrangelo A. Iron and steatohepatitis. J Gastroenterol Hepatol. 2012;27 Suppl 2:42-46. [PMID: 22320915 DOI: 10.1111/j.1440-1746.2011.07014.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
90 Manco M, Alisi A, Real JF, Equitani F, Devito R, Valenti L, Nobili V. Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease. Journal of Hepatology 2011;55:647-53. [DOI: 10.1016/j.jhep.2010.12.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
91 Shi KQ, Tang JZ, Zhu XL, Ying L, Li DW, Gao J, Fang YX, Li GL, Song YJ, Deng ZJ, Wu JM, Tang KF. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol. 2014;29:1149-1158. [PMID: 24476011 DOI: 10.1111/jgh.12519] [Cited by in Crossref: 89] [Cited by in F6Publishing: 73] [Article Influence: 11.1] [Reference Citation Analysis]
92 Feldman A, Aigner E, Weghuber D, Paulmichl K. The Potential Role of Iron and Copper in Pediatric Obesity and Nonalcoholic Fatty Liver Disease. Biomed Res Int. 2015;2015:287401. [PMID: 26273604 DOI: 10.1155/2015/287401] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
93 Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, Collier J, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 2016;64:308-315. [PMID: 26471505 DOI: 10.1016/j.jhep.2015.10.009] [Cited by in Crossref: 116] [Cited by in F6Publishing: 105] [Article Influence: 16.6] [Reference Citation Analysis]
94 Fargion S, Valenti L, Fracanzani AL. Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. Dig Liver Dis. 2011;43:89-95. [PMID: 20739232 DOI: 10.1016/j.dld.2010.07.006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
95 Terán Lantarón A, Crespo García J. [Non-alcoholic fatty liver disease. How and who to screen]. Gastroenterol Hepatol 2011;34:278-88. [PMID: 21429628 DOI: 10.1016/j.gastrohep.2010.11.010] [Reference Citation Analysis]
96 Adams LA, Crawford DH, Stuart K, House MJ, St Pierre TG, Webb M, Ching HL, Kava J, Bynevelt M, MacQuillan GC, Garas G, Ayonrinde OT, Mori TA, Croft KD, Niu X, Jeffrey GP, Olynyk JK. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology. 2015;61:1555-1564. [PMID: 25524401 DOI: 10.1002/hep.27662] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 8.4] [Reference Citation Analysis]
97 Fracanzani AL, Valenti L, Bugianesi E, Vanni E, Grieco A, Miele L, Consonni D, Fatta E, Lombardi R, Marchesini G. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol. 2011;54:1244-1249. [PMID: 21145841 DOI: 10.1016/j.jhep.2010.09.037] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 6.1] [Reference Citation Analysis]
98 O’Brien J, Powell LW. Non-alcoholic fatty liver disease: is iron relevant? Hepatol Int. 2012;6:332-341. [PMID: 22020821 DOI: 10.1007/s12072-011-9304-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
99 Mazhar K. The Future of Nonalcoholic Fatty Liver Disease Treatment. Med Clin North Am 2019;103:57-69. [PMID: 30466676 DOI: 10.1016/j.mcna.2018.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
100 Rodrigues de Morais T, Gambero A. Iron chelators in obesity therapy – Old drugs from a new perspective? European Journal of Pharmacology 2019;861:172614. [DOI: 10.1016/j.ejphar.2019.172614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Marti-Aguado D, Rodríguez-Ortega A, Mestre-Alagarda C, Bauza M, Valero-Pérez E, Alfaro-Cervello C, Benlloch S, Pérez-Rojas J, Ferrández A, Alemany-Monraval P, Escudero-García D, Monton C, Aguilera V, Alberich-Bayarri Á, Serra MÁ, Marti-Bonmati L. Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease. Aliment Pharmacol Ther 2021;53:160-71. [PMID: 32981113 DOI: 10.1111/apt.16100] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Nelson JE, Klintworth H, Kowdley KV. Iron metabolism in Nonalcoholic Fatty Liver Disease. Curr Gastroenterol Rep. 2012;14:8-16. [PMID: 22124850 DOI: 10.1007/s11894-011-0234-4] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 6.9] [Reference Citation Analysis]
103 Valenti L, Canavesi E, Galmozzi E, Dongiovanni P, Rametta R, Maggioni P, Maggioni M, Fracanzani AL, Fargion S. Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2010;53:927-933. [PMID: 20739079 DOI: 10.1016/j.jhep.2010.05.023] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
104 Wang Q, Ye F, Ma P, Chen F, Che Y, Zhao X, Yang L. Quantitative magnetic resonance imaging evaluation of hepatic fat content with iron deposition: will it be disturbed? J Int Med Res 2019;47:1958-74. [PMID: 30859893 DOI: 10.1177/0300060519836033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
105 Lunova M, Trautwein C, Strnad P, Nahon P. Reply to: "Hepatic hepcidin expression is decreased in cirrhosis and HCC". J Hepatol 2015;62:979-80. [PMID: 25463534 DOI: 10.1016/j.jhep.2014.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
106 Tariq Z, Green CJ, Hodson L. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? Liver Int 2014;34:e180-90. [DOI: 10.1111/liv.12523] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 8.4] [Reference Citation Analysis]
107 Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism 2020;111S:154183. [PMID: 32061907 DOI: 10.1016/j.metabol.2020.154183] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
108 Dongiovanni P, Ruscica M, Rametta R, Recalcati S, Steffani L, Gatti S, Girelli D, Cairo G, Magni P, Fargion S. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol. 2013;182:2254-2263. [PMID: 23578384 DOI: 10.1016/j.ajpath.2013.02.019] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 9.4] [Reference Citation Analysis]
109 Handa P, Maliken BD, Nelson JE, Hennessey KA, Akhila Vemulakonda L, Morgan-stevenson V, Dhillon BK, Gupta R, Yeh MM, Kowdley KV. Differences In Hepatic Expression of Iron, Inflammation and Stress-Related Genes in Patients with Nonalcoholic Steatohepatitis. Annals of Hepatology 2017;16:77-85. [DOI: 10.5604/16652681.1226818] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
110 Ryan JD, Armitage AE, Cobbold JF, Banerjee R, Borsani O, Dongiovanni P, Neubauer S, Morovat R, Wang LM, Pasricha SR. Hepatic iron is the major determinant of serum ferritin in NAFLD patients. Liver Int. 2017; Epub ahead of print. [PMID: 28679028 DOI: 10.1111/liv.13513] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
111 Danford CJ, Yao ZM, Jiang ZG. Non-alcoholic fatty liver disease: a narrative review of genetics. J Biomed Res 2018;32:389-400. [PMID: 30355853 DOI: 10.7555/JBR.32.20180045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
112 Dongiovanni P, Meroni M, Baselli G, Mancina RM, Ruscica M, Longo M, Rametta R, Cespiati A, Pelusi S, Ferri N, Ranzani V, Nobili V, Pihlajamaki J, Fracanzani AL, Badiali S, Petta S, Fargion S, Romeo S, Kozlitina J, Valenti L. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. J Lipid Res 2019;60:1144-53. [PMID: 30918065 DOI: 10.1194/jlr.P090449] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
113 Padda RS, Gkouvatsos K, Guido M, Mui J, Vali H, Pantopoulos K. A high-fat diet modulates iron metabolism but does not promote liver fibrosis in hemochromatotic Hjv⁻/⁻ mice. Am J Physiol Gastrointest Liver Physiol 2015;308:G251-61. [PMID: 25501544 DOI: 10.1152/ajpgi.00137.2014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
114 Dongiovanni P, Valenti L. A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2017;18:E1534. [PMID: 28714900 DOI: 10.3390/ijms18071534] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
115 Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Int J Endocrinol 2015;2015:343828. [PMID: 26064107 DOI: 10.1155/2015/343828] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
116 Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. Journal of Hepatology 2018;68:268-79. [DOI: 10.1016/j.jhep.2017.09.003] [Cited by in Crossref: 284] [Cited by in F6Publishing: 282] [Article Influence: 71.0] [Reference Citation Analysis]
117 Valenti L, Fracanzani AL, Dongiovanni P, Rovida S, Rametta R, Fatta E, Pulixi EA, Maggioni M, Fargion S. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014; 20(11): 3002-3010 [PMID: 24659891 DOI: 10.3748/wjg.v20.i11.3002] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 55] [Article Influence: 7.4] [Reference Citation Analysis]
118 Macías-Rodríguez RU, Inzaugarat ME, Ruiz-Margáin A, Nelson LJ, Trautwein C, Cubero FJ. Reclassifying Hepatic Cell Death during Liver Damage: Ferroptosis-A Novel Form of Non-Apoptotic Cell Death?Int J Mol Sci. 2020;21. [PMID: 32121273 DOI: 10.3390/ijms21051651] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
119 Izawa T, Murakami H, Wijesundera KK, Golbar HM, Kuwamura M, Yamate J. Inflammatory regulation of iron metabolism during thioacetamide-induced acute liver injury in rats. Exp Toxicol Pathol. 2014;66:155-162. [PMID: 24373749 DOI: 10.1016/j.etp.2013.12.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
120 Valenti L, Motta BM, Alisi A, Sartorelli R, Buonaiuto G, Dongiovanni P, Rametta R, Pelusi S, Fargion S, Nobili V. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2012;54:588-593. [PMID: 22157924 DOI: 10.1097/mpg.0b013e3182442a55] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
121 Shi KQ, Fan YC, Liu WY, Li LF, Chen YP, Zheng MH. Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. Mol Biol Rep. 2012;39:9715-9722. [PMID: 22718512 DOI: 10.1007/s11033-012-1836-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
122 Fargion S, Valenti L, Fracanzani AL. Role of iron in hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2014;3:108-10. [PMID: 30992900 DOI: 10.1002/cld.350] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
123 Taliento AE, Dallio M, Federico A, Prati D, Valenti L. Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease. Int J Environ Res Public Health 2019;16:E2755. [PMID: 31375010 DOI: 10.3390/ijerph16152755] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
124 Lucas C, Lucas G, Lucas N, Krzowska-Firych J, Tomasiewicz K. A systematic review of the present and future of non-alcoholic fatty liver disease. Clin Exp Hepatol 2018;4:165-74. [PMID: 30324141 DOI: 10.5114/ceh.2018.78120] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
125 Yaqoob U, Luo F, Greuter T, Jalan Sakrikar N, Sehrawat TS, Lu J, Hu X, Gao J, Kostallari E, Chen J, Arab JP, Martin-Mateos R, Cao S, Shah VH. GIPC-Regulated IGFBP-3 Promotes HSC Migration In Vitro and Portal Hypertension In Vivo Through a β1-Integrin Pathway. Cell Mol Gastroenterol Hepatol 2020;10:545-59. [PMID: 32447051 DOI: 10.1016/j.jcmgh.2020.05.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
126 van de Wier B, Balk JM, Haenen GR, Giamouridis D, Bakker JA, Bast BC, den Hartog GJ, Koek GH, Bast A. Elevated citrate levels in non-alcoholic fatty liver disease: the potential of citrate to promote radical production. FEBS Lett. 2013;587:2461-2466. [PMID: 23792160 DOI: 10.1016/j.febslet.2013.06.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
127 Lebovics E, Rubin J. Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Diabetes Metab Res Rev. 2011;27:419-424. [PMID: 21425426 DOI: 10.1002/dmrr.1198] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
128 Britton LJ, Subramaniam VN, Crawford DH. Iron and non-alcoholic fatty liver disease. World J Gastroenterol 2016; 22(36): 8112-8122 [PMID: 27688653 DOI: 10.3748/wjg.v22.i36.8112] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
129 Rives C, Fougerat A, Ellero-Simatos S, Loiseau N, Guillou H, Gamet-Payrastre L, Wahli W. Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants. Biomolecules 2020;10:E1702. [PMID: 33371482 DOI: 10.3390/biom10121702] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
130 Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20(42): 15539-15548 [PMID: 25400438 DOI: 10.3748/wjg.v20.i42.15539] [Cited by in CrossRef: 165] [Cited by in F6Publishing: 140] [Article Influence: 20.6] [Reference Citation Analysis]
131 Dongiovanni P, Lanti C, Gatti S, Rametta R, Recalcati S, Maggioni M, Fracanzani AL, Riso P, Cairo G, Fargion S, Valenti L. High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload. PLoS One. 2015;10:e0116855. [PMID: 25647178 DOI: 10.1371/journal.pone.0116855] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
132 Chen YY, Yeh MM. Non-alcoholic fatty liver disease: A review with clinical and pathological correlation. J Formos Med Assoc 2021;120:68-77. [PMID: 32654868 DOI: 10.1016/j.jfma.2020.07.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
133 Beaton MD. Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol. 2012;26:353-357. [PMID: 22720278 DOI: 10.1155/2012/725468] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
134 Anstee QM, Daly AK, Day CP. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim Biophys Acta. 2011;1812:1557-1566. [PMID: 21840395 DOI: 10.1016/j.bbadis.2011.07.017] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
135 Lu S, Bennett RG, Kharbanda KK, Harrison-Findik DD. Lack of hepcidin expression attenuates steatosis and causes fibrosis in the liver. World J Hepatol 2016; 8(4): 211-225 [PMID: 26855692 DOI: 10.4254/wjh.v8.i4.211] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
136 Kumei S, Yuhki KI, Kojima F, Kashiwagi H, Imamichi Y, Okumura T, Narumiya S, Ushikubi F. Prostaglandin I2 suppresses the development of diet-induced nonalcoholic steatohepatitis in mice. FASEB J 2018;32:2354-65. [PMID: 29247122 DOI: 10.1096/fj.201700590R] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
137 Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011;53:791-799. [PMID: 21319195 DOI: 10.1002/hep.24123] [Cited by in Crossref: 191] [Cited by in F6Publishing: 183] [Article Influence: 17.4] [Reference Citation Analysis]
138 Murali AR, Gupta A, Brown K. Systematic review and meta-analysis to determine the impact of iron depletion in dysmetabolic iron overload syndrome and non-alcoholic fatty liver disease. Hepatol Res 2018;48:E30-41. [PMID: 28593739 DOI: 10.1111/hepr.12921] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
139 Kramer JA, Grindley J, Crowell AM, Makaron L, Kohli R, Kirby M, Mansfield KG, Wachtman LM. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Vet Pathol 2015;52:404-13. [PMID: 24913270 DOI: 10.1177/0300985814537839] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
140 Atarashi M, Izawa T, Miyagi R, Ohji S, Hashimoto A, Kuwamura M, Yamate J. Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis. Nutrients 2018;10:E175. [PMID: 29401710 DOI: 10.3390/nu10020175] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
141 Sharp PA. New insights into the role of iron in the development of nonalcoholic fatty liver disease. Hepatology. 2010;52:408-410. [PMID: 20683940 DOI: 10.1002/hep.23774] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
142 Robinson KE, Shah VH. Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease. Transl Gastroenterol Hepatol 2020;5:49. [PMID: 33073044 DOI: 10.21037/tgh.2019.12.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
143 Regev A, Palmer M, Avigan MI, Dimick-Santos L, Treem WR, Marcinak JF, Seekins D, Krishna G, Anania FA, Freston JW, Lewis JH, Sanyal AJ, Chalasani N. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2019;49:702-13. [PMID: 30761572 DOI: 10.1111/apt.15153] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
144 Pickett-Blakely O, Young K, Carr RM. Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis. Cell Mol Gastroenterol Hepatol. 2018;6:451-462. [PMID: 30294653 DOI: 10.1016/j.jcmgh.2018.07.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
145 Edelman D, Kalia H, Delio M, Alani M, Krishnamurthy K, Abd M, Auton A, Wang T, Wolkoff AW, Morrow BE. Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population. Mol Genet Genomic Med 2015;3:558-69. [PMID: 26740948 DOI: 10.1002/mgg3.168] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
146 Graham RM, Chua ACG, Carter KW, Delima RD, Johnstone D, Herbison CE, Firth MJ, O'leary R, Milward EA, Olynyk JK, Trinder D. Hepatic iron loading in mice increases cholesterol biosynthesis. Hepatology 2010;52:462-71. [DOI: 10.1002/hep.23712] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
147 Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World J Gastroenterol 2016; 22(29): 6742-6756 [PMID: 27547017 DOI: 10.3748/wjg.v22.i29.6742] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
148 Motawi TK, Shaker OG, Ismail MF, Sayed NH. Genetic variants associated with the progression of hepatocellular carcinoma in hepatitis C Egyptian patients. Gene 2013;527:516-20. [PMID: 23845776 DOI: 10.1016/j.gene.2013.06.053] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
149 Vela D. Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker. Mol Med. 2018;24:5. [PMID: 30134796 DOI: 10.1186/s10020-018-0008-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
150 McKay A, Wilman HR, Dennis A, Kelly M, Gyngell ML, Neubauer S, Bell JD, Banerjee R, Thomas EL. Measurement of liver iron by magnetic resonance imaging in the UK Biobank population. PLoS One 2018;13:e0209340. [PMID: 30576354 DOI: 10.1371/journal.pone.0209340] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
151 Deugnier Y, Bardou-Jacquet É, Lainé F. Dysmetabolic iron overload syndrome (DIOS). Presse Med 2017;46:e306-11. [PMID: 29169710 DOI: 10.1016/j.lpm.2017.05.036] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
152 Anastasopoulos NT, Lianos GD, Tatsi V, Karampa A, Goussia A, Glantzounis GK. Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:1025-33. [PMID: 32746645 DOI: 10.1080/17474124.2020.1802244] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
153 Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res. 2012;42:1-14. [PMID: 21917086 DOI: 10.1111/j.1872-034x.2011.00872.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
154 Trépo E, Valenti L. Update on NAFLD genetics: From new variants to the clinic. J Hepatol 2020;72:1196-209. [PMID: 32145256 DOI: 10.1016/j.jhep.2020.02.020] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 32.5] [Reference Citation Analysis]
155 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1822] [Article Influence: 395.6] [Reference Citation Analysis]
156 Yuan S, Carter P, Vithayathil M, Kar S, Giovannucci E, Mason AM, Burgess S, Larsson SC. Iron Status and Cancer Risk in UK Biobank: A Two-Sample Mendelian Randomization Study. Nutrients 2020;12:E526. [PMID: 32092884 DOI: 10.3390/nu12020526] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
157 Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des. 2013;19:5219-5238. [PMID: 23394097 DOI: 10.2174/13816128113199990381] [Cited by in Crossref: 128] [Cited by in F6Publishing: 113] [Article Influence: 16.0] [Reference Citation Analysis]
158 Wagner J, Fillebeen C, Haliotis T, Charlebois E, Katsarou A, Mui J, Vali H, Pantopoulos K. Mouse models of hereditary hemochromatosis do not develop early liver fibrosis in response to a high fat diet. PLoS One 2019;14:e0221455. [PMID: 31442254 DOI: 10.1371/journal.pone.0221455] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
159 Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99-128. [PMID: 30343320 DOI: 10.1007/s00018-018-2947-0] [Cited by in Crossref: 109] [Cited by in F6Publishing: 118] [Article Influence: 27.3] [Reference Citation Analysis]
160 Vecchi C, Montosi G, Garuti C, Corradini E, Sabelli M, Canali S, Pietrangelo A. Gluconeogenic signals regulate iron homeostasis via hepcidin in mice. Gastroenterology. 2014;146:1060-1069. [PMID: 24361124 DOI: 10.1053/j.gastro.2013.12.016] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 7.9] [Reference Citation Analysis]
161 Guo C, Xue H, Guo T, Zhang W, Xuan WQ, Ren YT, Wang D, Chen YH, Meng YH, Gao HL, Zhao P. Recombinant human lactoferrin attenuates the progression of hepatosteatosis and hepatocellular death by regulating iron and lipid homeostasis in ob/ob mice. Food Funct 2020;11:7183-96. [PMID: 32756704 DOI: 10.1039/d0fo00910e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
162 Basuli D, Stevens RG, Torti FM, Torti SV. Epidemiological associations between iron and cardiovascular disease and diabetes. Front Pharmacol 2014;5:117. [PMID: 24904420 DOI: 10.3389/fphar.2014.00117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis]
163 Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16:377-386. [PMID: 31024089 DOI: 10.1038/s41575-019-0144-8] [Cited by in Crossref: 144] [Cited by in F6Publishing: 132] [Article Influence: 48.0] [Reference Citation Analysis]
164 Miyanishi K, Tanaka S, Sakamoto H, Kato J. The role of iron in hepatic inflammation and hepatocellular carcinoma. Free Radical Biology and Medicine 2019;133:200-5. [DOI: 10.1016/j.freeradbiomed.2018.07.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
165 Tariq R, Axley P, Singal AK. Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review. J Clin Exp Hepatol 2020;10:81-7. [PMID: 32025167 DOI: 10.1016/j.jceh.2019.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
166 Law K, Brunt EM. Nonalcoholic fatty liver disease. Clin Liver Dis. 2010;14:591-604. [PMID: 21055684 DOI: 10.1016/j.cld.2010.07.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
167 Murotomi K, Arai S, Uchida S, Endo S, Mitsuzumi H, Tabei Y, Yoshida Y, Nakajima Y. Involvement of splenic iron accumulation in the development of nonalcoholic steatohepatitis in Tsumura Suzuki Obese Diabetes mice. Sci Rep 2016;6:22476. [PMID: 26932748 DOI: 10.1038/srep22476] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
168 Valenti L. Uncovering the genetics of cirrhosis: New plots for the usual suspects. Liver Int 2020;40:281-2. [PMID: 31967399 DOI: 10.1111/liv.14333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
169 Miyake T, Kumagi T, Furukawa S, Tokumoto Y, Hirooka M, Abe M, Hiasa Y, Matsuura B, Onji M. Non-alcoholic fatty liver disease: factors associated with its presence and onset. J Gastroenterol Hepatol. 2013;28 Suppl 4:71-78. [PMID: 24251708 DOI: 10.1111/jgh.12251] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
170 Van De Wier B, Koek GH, Bast A, Haenen GRMM. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Critical Reviews in Food Science and Nutrition 2015;57:834-55. [DOI: 10.1080/10408398.2014.952399] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 11.0] [Reference Citation Analysis]
171 Lu S, Natarajan SK, Mott JL, Kharbanda KK, Harrison-Findik DD. Ceramide Induces Human Hepcidin Gene Transcription through JAK/STAT3 Pathway. PLoS One 2016;11:e0147474. [PMID: 26807955 DOI: 10.1371/journal.pone.0147474] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]